Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.
Stocks · News reference
Under the Radar: 3 Boring Small Caps That Could Return 10x
Investors spend an enormous amount of time searching for the next stock that can rise 10 times in value. They study disruptive technologies, enormous addressable markets, charismatic founders, and whatever investment
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target
Cantor Fitzgerald analyst Sarah James reiterates Bioventus (NASDAQ:BVS) with a Overweight and maintains $15 price target.
Deal Dispatch: Bending Spoons Acquires Airtable, Bain Capital Buys Gong Cha Global, Salad and Go Bankruptcy
Major M&A deals include Visa buys BioCatch, Apollo Global nabs EasyJet, QVC emerges from Chapter 11 bankruptcy.
Bioventus shares are trading higher after the company reported strong Q2 financial results and announced a review of strategic alternatives.
8-K filing — Coda Octopus Group, Inc. (CODA)
Filed: 2026-07-06 AccNo: 0001493152-26-032038 Size: 206 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Coda Octopus Group Reports Q2 2026 Results: Full Earnings Call Transcript